Generex's New Plan: Spinout, Reverse Stock Split And Continued Focus On Oral Insulin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm believes buccal delivery of oral insulin will succeed where inhaled insulins have failed or stalled in development.
You may also be interested in...
Cautious FDA Is Obstacle For Burgeoning Diabetes Device Market
Is innovation in the diabetes device market being hampered by a slowdown in FDA approvals? That question was the unofficial, under-riding theme at the American Diabetes Association 71st Scientific Sessions in June.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.